H.C. Wainwright Remains a Buy on Omeros Corp (OMER)

By Carrie Williams

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Omeros Corp (OMERResearch Report) today and set a price target of $34. The company’s shares closed yesterday at $14.35.

Selvaraju noted:

“Valuation methodology, risks and uncertainties. We currently ascribe a total firm value of roughly $2.3B to Omeros based on OMIDRIA ($820M) and OMS721 ($1.5B). This translates into a target of $34.00 per share, based on 68M fully-diluted shares outstanding as of end-2019. We assume the redemption of the senior convertible notes in full after one year, using proceeds from a follow-on offering of common stock in late 2019.”

According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -14.0% and a 19.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Omeros Corp has an analyst consensus of Moderate Buy, with a price target consensus of $33, which is a 130.0% upside from current levels. In a report issued on December 6, Maxim Group also maintained a Buy rating on the stock with a $32 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $27 and a one-year low of $8.36. Currently, Omeros Corp has an average volume of 935.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Omeros Corp. operates as a biopharmaceutical company specializes in discovery, development, and commercializes of both small-molecule and protein therapeutics for large -market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.